FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899402018> ?p ?o ?g. }

• W2899402018 abstract "Abstract Background The IDSA recommends use of AZT in patients with a confirmed beta-lactam allergy for nosocomial Gram-negative infections. Despite this recommendation, there is limited data to suggest AZT is inferior to cephalosporins (CEP) for the treatment of Gram-negative infections. This study aims to evaluate clinical outcomes in bacteremic patients treated with either AZT or CEP therapy. Methods A single-center, retrospective chart review of adult patients with positive blood cultures for Escherichia coli, Klebsiella pneumoniae or Pseudomonas aeruginosa was conducted to compare clinical outcomes between those who received ≥ 48 hours of AZT or CEP therapy (cefepime or ceftriaxone). The following clinical outcomes were assessed: clinical cure, in-hospital mortality, post-infection length of stay (LOS), post-infection intensive care unit LOS, microbiologic cure and leukocytosis resolution. Results One-hundred and twenty-nine patients met criteria for evaluation: 41 received AZT and 88 received CEP therapy. At baseline, patients who received AZT were more likely to have renal dysfunction (34.1% vs. 18.2%, P = 0.046), receive synergistic antimicrobials (61% vs. 28.4%, P &lt; 0.001) and had a longer pre-infection LOS (1 day [0–2] vs. 0 [0–1], P = 0.032) compared with those who received CEP. Although in-hospital mortality rates were similar between both groups (2.4% vs. 3.4%, P = 1.000), there was a statistically significant difference in clinical cure rates (70.7% vs. 90.9%, P = 0.003), post-infection length of stay (7 days [5–10] vs. 5 [4–8], P = 0.007), and time to clinical cure (2.8 days (1.6–5.8) vs. 2.0 (1.2–2.9), P = 0.018) in the AZT and CEP groups respectively. In a multivariate logistic regression model, patients who received AZT were significantly less likely to achieve clinical cure (OR=0.187, 95% CI (0.058–0.597). In a pre-determined subgroup analysis, clinical cure rates varied in E. coli (72% vs. 94.4%, P = 0.009), K. pneumoniae (70% vs. 90.5%, P = 0.296) and P. aeruginosa (66.7% vs. 76.9%, P = 1.000) in the AZT and CEP group respectively. Conclusion Patients who receive aztreonam for Gram-negative bacteremia may be more likely to experience clinical failure. Larger, prospective studies are warranted to confirm these findings. Disclosures All authors: No reported disclosures." @default.
• W2899402018 created "2018-11-09" @default.
• W2899402018 creator A5000817766 @default.
• W2899402018 creator A5039081989 @default.
• W2899402018 creator A5047654670 @default.
• W2899402018 date "2018-11-01" @default.
• W2899402018 modified "2023-09-27" @default.
• W2899402018 title "1044. Aztreonam (AZT) vs. Cephalosporin (CEP) Therapy for the Treatment of Gram-Negative Bacteremia" @default.
• W2899402018 doi "https://doi.org/10.1093/ofid/ofy210.881" @default.
• W2899402018 hasPublicationYear "2018" @default.
• W2899402018 type Work @default.
• W2899402018 sameAs 2899402018 @default.
• W2899402018 citedByCount "0" @default.
• W2899402018 crossrefType "journal-article" @default.
• W2899402018 hasAuthorship W2899402018A5000817766 @default.
• W2899402018 hasAuthorship W2899402018A5039081989 @default.
• W2899402018 hasAuthorship W2899402018A5047654670 @default.
• W2899402018 hasBestOaLocation W28994020181 @default.
• W2899402018 hasConcept C126322002 @default.
• W2899402018 hasConcept C2776376669 @default.
• W2899402018 hasConcept C2776520383 @default.
• W2899402018 hasConcept C2777050379 @default.
• W2899402018 hasConcept C2778923028 @default.
• W2899402018 hasConcept C2779375183 @default.
• W2899402018 hasConcept C2779443120 @default.
• W2899402018 hasConcept C2779631663 @default.
• W2899402018 hasConcept C2780416669 @default.
• W2899402018 hasConcept C501593827 @default.
• W2899402018 hasConcept C64778159 @default.
• W2899402018 hasConcept C71924100 @default.
• W2899402018 hasConcept C86803240 @default.
• W2899402018 hasConcept C89423630 @default.
• W2899402018 hasConcept C94665300 @default.
• W2899402018 hasConceptScore W2899402018C126322002 @default.
• W2899402018 hasConceptScore W2899402018C2776376669 @default.
• W2899402018 hasConceptScore W2899402018C2776520383 @default.
• W2899402018 hasConceptScore W2899402018C2777050379 @default.
• W2899402018 hasConceptScore W2899402018C2778923028 @default.
• W2899402018 hasConceptScore W2899402018C2779375183 @default.
• W2899402018 hasConceptScore W2899402018C2779443120 @default.
• W2899402018 hasConceptScore W2899402018C2779631663 @default.
• W2899402018 hasConceptScore W2899402018C2780416669 @default.
• W2899402018 hasConceptScore W2899402018C501593827 @default.
• W2899402018 hasConceptScore W2899402018C64778159 @default.
• W2899402018 hasConceptScore W2899402018C71924100 @default.
• W2899402018 hasConceptScore W2899402018C86803240 @default.
• W2899402018 hasConceptScore W2899402018C89423630 @default.
• W2899402018 hasConceptScore W2899402018C94665300 @default.
• W2899402018 hasLocation W28994020181 @default.
• W2899402018 hasLocation W28994020182 @default.
• W2899402018 hasLocation W28994020183 @default.
• W2899402018 hasOpenAccess W2899402018 @default.
• W2899402018 hasPrimaryLocation W28994020181 @default.
• W2899402018 hasRelatedWork W1976539005 @default.
• W2899402018 hasRelatedWork W2010668709 @default.
• W2899402018 hasRelatedWork W2045795488 @default.
• W2899402018 hasRelatedWork W2064473343 @default.
• W2899402018 hasRelatedWork W2068640348 @default.
• W2899402018 hasRelatedWork W2085681380 @default.
• W2899402018 hasRelatedWork W2108978547 @default.
• W2899402018 hasRelatedWork W2139069485 @default.
• W2899402018 hasRelatedWork W2144729514 @default.
• W2899402018 hasRelatedWork W2899402018 @default.
• W2899402018 isParatext "false" @default.
• W2899402018 isRetracted "false" @default.
• W2899402018 magId "2899402018" @default.
• W2899402018 workType "article" @default.